Menu UF Health Home Menu

Michael Katovich, Ph.D.

Michael Katovich





PHONE: 352-273-7690

CV: Link to CV


Research Interests

The Katovich Lab studies the various components of the endocrine renin-angiotensin system (RAS) and their effects on hypertension and associated cardiovascular organ damage. Over the past several years more components of the RAS have been elucidated and we have utilized gene therapy approaches to enhance and/or modify certain aspects of the RAS in order to reduce cardiovascular risks in hypertension and diabetes. We utilize in vivo animal models as well as cell culture protocols to evaluate the physiological, pharmacological and morphological effects of manipulations of the RAS. Currently we are looking at the effects of overexpressing components of the RAS such as the AT2R, ACE2 and Ang-(1-7) in models of hypertension, stroke, and coronary artery ligation to determine the “beneficial” effects of these RAS components on various end organs. Utilization of gene therapy approaches and classical physiological methods (such as vascular smooth muscle reactivity, in vitro heart perfusion, metabolic studies, etc) aid in not only the understanding of the mechanism of actions of existing therapeutic agents but also leads to new innovative therapeutic effects in treating cardiovascular and metabolic diseases.

Membership Professional Organizations

  • American Physiological Society ‑ Since 1979
  • Endocrine Society ‑ Since 1983
  • Phi Lambda Sigma (Pharmacy Leadership Society) – Since 1985
  • American Diabetes Association – Since 1989
  • American Association of Colleges of Pharmacy – Since 1988
  • Council on Complications, American Diabetes Association – Since 1990
  • Association for Supervision and Curriculum Development- Since 1993
  • American Society of Hypertension-Since 1996
  • International Society for Gravitational Physiology – since 1996, President 1999-200

Recent Publications